Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135

ACS Chemical Neuroscience

Volumn 6, Issue 8, 2015, Pages 1445-1458

  Banister, Samuel D ^a,b   Stuart, Jordyn ^c   Kevin, Richard C ^d   Edington, Amelia ^c   Longworth, Mitchell ^b   Wilkinson, Shane M ^b   Beinat, Corinne ^a,b   Buchanan, Alexandra S ^a,e   Hibbs, David E ^d   Glass, Michelle ^f   Connor, Mark ^c   McGregor, Iain S ^d   Kassiou, Michael ^b,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

AM 2201; Cannabinoid; JWH 018; PB 22; THC; XLR 11

Indexed keywords

(1 PENTYL 1H INDOL 3 YL)(2,2,3,3 TETRAMETHYLCYCLOPROPYL) METHANONE; 1 (5 FLUOROPENTYL) 3 (1 NAPHTHOYL)INDOLE; 1 (5 FLUOROPENTYL)INDOLE 3 CARBOXYLIC ACID; 1 PENTYLINDOLE 3 CARBOXYLIC ACID; 1H INDOLE 3 YL(2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; CANNABINOID RECEPTOR AGONIST; DESIGNER DRUG; FLUORINE DERIVATIVE; N (1 ADAMANTYL) 1 PENTYL 1H INDOLE 3 CARBOXAMIDE; N (ADAMANTAN 1 YL) 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDE; N (ADAMANTAN 1 YLMETHYL) 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDE; N (CYCLOHEXYLMETHYL) 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDE; N BENZYL 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDE; N CYCLOHEXYL 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDE; N PHENYL 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDE; QUINOLIN 8 YL 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXYLATE; QUINOLIN 8 YL 1 PENTYL 1H INDOLE 3 CARBOXYLATE; UNCLASSIFIED DRUG; [1 (5 ACETOXYPENTYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [1 (5 FLUOROPENTYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [1 (5 HYDROXYPENTYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; (1-PENTYL-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE; 1-((5-FLUOROPENTYL)-1H-INDOL-3-YL)-(NAPHTHALEN-1-YL)METHANONE; 1-PENTYL-1H-INDOLE-3-CARBOXYLIC ACID 8-QUINOLINYL ESTER; 1-PENTYL-3-(1-NAPHTHOYL)INDOLE; ADAMANTANE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CNR1 PROTEIN, HUMAN; CNR2 PROTEIN, HUMAN; INDOLE DERIVATIVE; N-(ADAMANTAN-1-YL)-1-(5-FLUOROPENTYL)-1H-INDOLE-3-CARBOXAMIDE; NAPHTHALENE DERIVATIVE; QUINOLINE DERIVATIVE; XLR-11;

ACYLATION; ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; BODY TEMPERATURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG ACTIVITY; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; EC50; HEART RATE; HYDROLYSIS; HYPERPOLARIZATION; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE POTENTIAL; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TELEMETRY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; MALE; METABOLISM; PRECLINICAL STUDY; TUMOR CELL LINE; WISTAR RAT;

RATTUS;

ADAMANTANE; ANIMALS; CANNABINOIDS; CELL LINE, TUMOR; DESIGNER DRUGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEART RATE; HUMANS; HYPOTHERMIA; INDOLES; MALE; MICE; MOLECULAR STRUCTURE; NAPHTHALENES; QUINOLINES; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TELEMETRY;

EID: 84937530248     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00107     Document Type: Article

References (57)

1. European Monitoring Centre for Drugs and Drug Addiction (2015), New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015), Publications Office of the European Union, Luxembourg.
2. Maxwell, J. C. (2014) Psychoactive substances-Some new, some old: A scan of the situation in the U.S. Drug Alcohol Depend. 134, 71-77
3. Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., and Frank, R. A. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch. Gen. Psychiatry 58, 322-328
4. D'Ambra, T. E., Estep, K. G., Bell, M. R., Eissenstat, M. A., Josef, K. A., Ward, S. J., Haycock, D. A., Baizman, E. R., and Casiano, F. M. (1992) Conformationally restrained analogs of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor J. Med. Chem. 35, 124-135
5. Auwarter, V., Dresen, S., Weinmann, W., Muller, M., Putz, M., and Ferreiros, N. (2009) 'Spice' and other herbal blends: Harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 44, 832-837
6. Wilkinson, S. M., Banister, S. D., and Kassiou, M. (2015) Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids Aust. J. Chem. 68, 4-8
7. Makriyannis, A. and Deng, H. Preparation of cannabimimetic indole derivatives with cannabinoid CB1 or CB2 receptor binding affinity. World patent WO 2001/028557, 26 April, 2001.
8. Nakajima, J.i., Takahashi, M., Nonaka, R., Seto, T., Suzuki, J., Yoshida, M., Kanai, C., and Hamano, T. (2011) Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays Forensic Toxicol. 29, 132-141
9. Sobolevsky, T., Prasolov, I., and Rodchenkov, G. (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids Drug Test. Anal. 4, 745-753
10. Chung, H., Choi, H., Heo, S., Kim, E., and Lee, J. (2014) Synthetic cannabinoids abused in South Korea: Drug identifications by the National Forensic Service from 2009 to June 2013 Forensic Toxicol. 32, 82-88
11. Frost, J. M., Dart, M. J., Tietje, K. R., Garrison, T. R., Grayson, G. K., Daza, A. V., El-Kouhen, O. F., Miller, L. N., Li, L., Yao, B. B., Hsieh, G. C., Pai, M., Zhu, C. Z., Chandran, P., and Meyer, M. D. (2008) Indol-3-yl-tetramethylcyclopropyl ketones: Effects of indole ring substitution on CB2 cannabinoid receptor activity J. Med. Chem. 51, 1904-1912
12. Frost, J. M., Dart, M. J., Tietje, K. R., Garrison, T. R., Grayson, G. K., Daza, A. V., El-Kouhen, O. F., Yao, B. B., Hsieh, G. C., Pai, M., Zhu, C. Z., Chandran, P., and Meyer, M. D. (2010) Indol-3-ylcycloalkyl ketones: Effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity J. Med. Chem. 53, 295-315
13. Kavanagh, P., Grigoryev, A., Savchuk, S., Mikhura, I., and Formanovsky, A. (2013) UR-144 in products sold via the Internet: Identification of related compounds and characterization of pyrolysis products Drug Test. Anal. 5, 683-692
14. Shevyrin, V., Melkozerov, V., Nevero, A., Eltsov, O., Morzherin, Y., and Shafran, Y. (2013) Identification and analytical properties of new synthetic cannabimimetics bearing 2,2,3,3-tetramethylcyclopropanecarbonyl moiety Forensic Sci. Int. 226, 62-73
15. Zuba, D. and Byrska, B. (2013) Analysis of the prevalence and coexistence of synthetic cannabinoids in "herbal high" products in Poland Forensic Toxicol. 31, 21-30
16. Seely, K. A., Patton, A. L., Moran, C. L., Womack, M. L., Prather, P. L., Fantegrossi, W. E., Radominska-Pandya, A., Endres, G. W., Channell, K. B., Smith, N. H., McCain, K. R., James, L. P., and Moran, J. H. (2013) Forensic investigation of K2, Spice, and "bath salt" commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds Forensic Sci. Int. 233, 416-422
17. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., and Goda, Y. (2013) URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products Forensic Sci. Int. 227, 21-32
18. Choi, H., Heo, S., Kim, E., Hwang, B. Y., Lee, C., and Lee, J. (2013) Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking Forensic Toxicol. 31, 86-92
19. Langer, N., Lindigkeit, R., Schiebel, H. M., Ernst, L., and Beuerle, T. (2014) Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: a snapshot of the German situation in the autumn of 2012 Drug Test. Anal. 6, 59-71
20. Thornton, S. L., Wood, C., Friesen, M. W., and Gerona, R. R. (2013) Synthetic cannabinoid use associated with acute kidney injury Clin. Toxicol. 51, 189-190
21. Buser, G. L., Gerona, R. R., Horowitz, B. Z., Vian, K. P., Troxell, M. L., Hendrickson, R. G., Houghton, D. C., Rozansky, D., Su, S. W., and Leman, R. F. (2014) Acute kidney injury associated with smoking synthetic cannabinoid Clin. Toxicol. 52, 664-673
22. Takematsu, M., Hoffman, R. S., Nelson, L. S., Schechter, J. M., Moran, J. H., and Wiener, S. W. (2014) A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid Clin. Toxicol. 52, 973-975
23. Wiley, J. L., Marusich, J. A., Lefever, T. W., Grabenauer, M., Moore, K. N., and Thomas, B. F. (2013) Cannabinoids in disguise: Δ9-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles Neuropharmacology 75, 145-154
24. Shevyrin, V., Melkozerov, V., Nevero, A., Eltsov, O., and Shafran, Y. (2013) Analytical characterization of some synthetic cannabinoids, derivatives of indole-3-carboxylic acid Forensic Sci. Int. 232, 1-10
25. Uchiyama, N., Matsuda, S., Kawamura, M., Kikura-Hanajiri, R., and Goda, Y. (2014) Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products Forensic Toxicol. 32, 9-18
26. Uchiyama, N., Matsuda, S., Kawamura, M., Kikura-Hanajiri, R., and Goda, Y. (2013) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products Forensic Toxicol. 31, 223-240
27. McQuade, D., Hudson, S., Dargan, P. I., and Wood, D. M. (2013) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201 Eur. J. Clin. Pharmacol. 69, 373-376
28. Gugelmann, H., Gerona, R., Li, C., Tsutaoka, B., Olson, K. R., and Lung, D. (2014) Crazy Monkey poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid Clin. Toxicol. 52, 635-638
29. Schep, L., Slaughter, R., Hudson, S., Place, R., and Watts, M. (2014) Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues Hum. Exp. Toxicol. 10.1177/0960327114550886
30. Behonick, G., Shanks, K. G., Firchau, D. J., Mathur, G., Lynch, C. F., Nashelsky, M., Jaskierny, D. J., and Meroueh, C. (2014) Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22 J. Anal. Toxicol. 38, 559-562
31. Takayama, T., Suzuki, M., Todoroki, K., Inoue, K., Min, J. Z., Kikura-Hanajiri, R., Goda, Y., and Toyooka, T. (2014) UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and alpha-PVT, by human liver microsome Biomed. Chromatogr. 28, 831-838
32. Thomsen, R., Nielsen, L. M., Holm, N. B., Rasmussen, H. B., Linnet, K., and INDICES Consortium (2014) Synthetic cannabimimetic agents metabolized by carboxylesterases Drug Test. Anal. 10.1002/dta.1731
33. Wohlfarth, A., Gandhi, A. S., Pang, S., Zhu, M., Scheidweiler, K. B., and Huestis, M. A. (2014) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry Anal. Bioanal. Chem. 406, 1763-1780
34. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., and Goda, Y. (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products Forensic Toxicol. 30, 114-125
35. Sobolevsky, T., Prasolov, I., and Rodchenkov, G. (2015) Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue Drug Test. Anal. 7, 131-142
36. Banister, S. D., Wilkinson, S. M., Longworth, M., Stuart, J., Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D. E., Glass, M., Connor, M., McGregor, I. S., and Kassiou, M. (2013) The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse ACS Chem. Neurosci. 4, 1081-1092
37. Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., and Prather, P. L. (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity PLoS One 6 e21917
38. Chimalakonda, K. C., Seely, K. A., Bratton, S. M., Brents, L. K., Moran, C. L., Endres, G. W., James, L. P., Hollenberg, P. F., Prather, P. L., Radominska-Pandya, A., and Moran, J. H. (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands Drug Metab. Dispos. 40, 2174-2184
39. Rajasekaran, M., Brents, L. K., Franks, L. N., Moran, J. H., and Prather, P. L. (2013) Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors Toxicol. Appl. Pharmacol. 269, 100-108
40. Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A., and Prather, P. L. (2014) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: Mechanism underlying greater toxicity? Life Sci. 97, 45-54
41. Grigoryev, A., Kavanagh, P., and Melnik, A. (2013) The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography-mass spectrometry Drug Test. Anal. 5, 110-115
42. Wohlfarth, A., Pang, S., Zhu, M., Gandhi, A. S., Scheidweiler, K. B., Liu, H. F., and Huestis, M. A. (2013) First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry Clin. Chem. 59, 1638-1648
43. Jang, M., Yang, W., Shin, I., Choi, H., Chang, H., and Kim, E. (2014) Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse Int. J. Leg. Med. 128, 285-294
44. Kanamori, T., Kanda, K., Yamamuro, T., Kuwayama, K., Tsujikawa, K., Iwata, Y. T., and Inoue, H. (2015) Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine Drug Test. Anal. 10.1002/dta.1765
45. Hutter, M., Moosmann, B., Kneisel, S., and Auwärter, V. (2013) Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism J. Mass Spectrom. 48, 885-894
46. European Monitoring Centre for Drugs and Drug Addiction (2014), EMCDDA-Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA, Implementation reports, Publications Office of the European Union, Luxembourg.
47. Okauchi, T., Itonaga, M., Minami, T., Owa, T., Kitoh, K., and Yoshino, H. (2000) A general method for acylation of indoles at the 3-position with acyl chlorides in the presence of dialkylaluminum chloride Org. Lett. 2, 1485-1487
48. Grimsey, N. L., Graham, E. S., Dragunow, M., and Glass, M. (2010) Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: Implications for therapeutics Biochem. Pharmacol. 80, 1050-1062
49. Knapman, A., Santiago, M., Du, Y. P., Bennallack, P. R., Christie, M. J., and Connor, M. (2013) A continuous, fluorescence-based assay of μ-opioid receptor activation in AtT-20 cells J. Biomol. Screening 18, 269-276
50. Atwood, B. K., Lopez, J., Wager-Miller, J., Mackie, K., and Straiker, A. (2011) Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis BMC Genomics 12 14
51. Wiley, J. L., Compton, D. R., Dai, D., Lainton, J. A. H., Phillips, M., Huffman, J. W., and Martin, B. R. (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids J. Pharmacol. Exp. Ther. 285, 995-1004
52. Wiley, J. L., Marusich, J. A., and Huffman, J. W. (2014) Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids Life Sci. 97, 55-63
53. Wiley, J. L., Lefever, T. W., Cortes, R. A., and Marusich, J. A. (2014) Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats Pharmacol., Biochem. Behav. 124, 123-128
54. Hine, B., Torrelio, M., and Gershon, S. (1977) Analgesic, heart rate, and temperature effects of Δ8-THC during acute and chronic administration to conscious rats Pharmacology 15, 65-72
55. Wiley, J. L., Marusich, J. A., Martin, B. R., and Huffman, J. W. (2012) 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice Drug Alcohol Depend. 123, 148-153
56. Bruker (2011) Apex2 suite of programs, Bruker AXS Inc., Madison, Wisconsin, USA.
57. Sheldrick, G. M. (2008) A short history of SHELX Acta Crystallogr. A64, 112-122